Two directors at Spyre Therapeutics executed massive open-market sales totaling $401.66M in a 7-day window, with the largest single sell ($399.66M by Fairmount Funds Management) representing ~4.6% of the $8.7B market cap. This is a highly material cluster sale that dwarfs routine insider activity and signals a significant reduction in insider alignment, likely ahead of a catalyst or valuation peak.
SYRE drugs
SYRE drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 24 $86.24entry
- T+1 · 5mo ago +2.82%α +2.67% · $88.67
- T+5 · 5mo ago +3.07%α +1.37% · $88.89
- T+20 · 4mo ago +14.99%α +13.06% · $99.17
- T+60 · 2mo ago +7.47%α +4.63% · $92.68
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two directors at Spyre Therapeutics executed massive open-market sales totaling $401.66M in a 7-day window, with the largest single sell ($399.66M by Fairmount Funds Management) representing ~4.6% of the $8.7B market cap. This is a highly material cluster sale that dwarfs routine insider activity and signals a significant reduction in insider alignment, likely ahead of a catalyst or valuation peak.
Key Financial Metrics
Key Facts
- Fairmount Funds Management LLC sold 4,684,781 shares at $85.31 for $399.66M on 2026-06-23
- Michael Thomas Henderson sold 20,000 shares at $100.00 for $2.00M on 2026-06-22
- Total cluster sale value: $401.66M, representing ~4.6% of $8.7B market cap
- Non-cash derivative conversions by Fairmount (16,667 and 666,680 shares at $0) preceded the sale
- Prior 30-day insider activity: 5 sells totaling $402.7M, making this cluster the dominant driver
- Analyst consensus is 96% bullish (22 Buy/1 Hold), creating a potential sentiment disconnect
Financial Impact
Insider sales of $401.66M represent ~4.6% of market cap, a highly material reduction in insider ownership
Risk Factors
- Insider sale of this magnitude often precedes negative catalysts or signals peak valuation
- Potential secondary offering or lockup expiration could further pressure shares
- Analyst consensus is overwhelmingly bullish, creating crowded positioning risk if sentiment shifts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-SYRE-1782266221792 |
Track record
36 reports on SYRE
8 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 15 of 20 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers